Abstract IA15: Targeting oligometastatic disease in prostate cancer

Abstract

Abstract Clinical reports of limited and treatable cancer metastases, a disease state that exists in a transitional zone between localized and widespread systemic disease, have been noted on occasion historically and termed oligometastasis (OM). The ramification of a diagnosis of oligometastasis is a change in treatment paradigm, i.e., if the primary cancer site (if still present) is controlled or resected, and the metastatic sites are ablated (surgically or with radiation), a prolonged disease-free interval, and perhaps even cure, may be possible. Contemporary imaging diagnostics are identifying more and more OM patients. For example, in prostate cancer the use of PSMA-Pyl PET imaging is leading to the diagnosis of many OM patients who have no disease on conventional clinical imaging. It is unclear if these are truly isolated sites of disease (curable) or simply a reflection of more widespread microscopic disease (incurable or at best a bridging therapy). This is especially true in the biochemical recurrence (bcr) space after primary treatment. We will present our experience with identifying and treating prostate cancer OM disease. Citation Format: Kenneth J. Pienta. Targeting oligometastatic disease in prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr IA15.